294 related articles for article (PubMed ID: 23696648)
1. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
Fujita M; Ieguchi K; Cedano-Prieto DM; Fong A; Wilkerson C; Chen JQ; Wu M; Lo SH; Cheung AT; Wilson MD; Cardiff RD; Borowsky AD; Takada YK; Takada Y
J Biol Chem; 2013 Jul; 288(27):19593-603. PubMed ID: 23696648
[TBL] [Abstract][Full Text] [Related]
2. Cross-talk between integrin α6β4 and insulin-like growth factor-1 receptor (IGF1R) through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions.
Fujita M; Ieguchi K; Davari P; Yamaji S; Taniguchi Y; Sekiguchi K; Takada YK; Takada Y
J Biol Chem; 2012 Apr; 287(15):12491-500. PubMed ID: 22351760
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.
Fujita M; Takada YK; Takada Y
J Biol Chem; 2013 Feb; 288(5):3059-69. PubMed ID: 23243309
[TBL] [Abstract][Full Text] [Related]
4. Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.
Cedano Prieto DM; Cheng Y; Chang CC; Yu J; Takada YK; Takada Y
PLoS One; 2017; 12(9):e0184285. PubMed ID: 28873464
[TBL] [Abstract][Full Text] [Related]
5. The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.
Saegusa J; Yamaji S; Ieguchi K; Wu CY; Lam KS; Liu FT; Takada YK; Takada Y
J Biol Chem; 2009 Sep; 284(36):24106-14. PubMed ID: 19578119
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1.
Takada Y; Takada YK; Fujita M
Cytokine Growth Factor Rev; 2017 Apr; 34():67-72. PubMed ID: 28190785
[TBL] [Abstract][Full Text] [Related]
7. Integrins αvβ3 and α4β1 act as coreceptors for fractalkine, and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1.
Fujita M; Takada YK; Takada Y
J Immunol; 2012 Dec; 189(12):5809-19. PubMed ID: 23125415
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Ligand and Shear Stress-induced Insulin-like Growth Factor 1 (IGF1) Signaling by the Integrin Pathway.
Tahimic CG; Long RK; Kubota T; Sun MY; Elalieh H; Fong C; Menendez AT; Wang Y; Vilardaga JP; Bikle DD
J Biol Chem; 2016 Apr; 291(15):8140-9. PubMed ID: 26865633
[TBL] [Abstract][Full Text] [Related]
9. Impaired IGF1R signaling in cells expressing longevity-associated human IGF1R alleles.
Tazearslan C; Huang J; Barzilai N; Suh Y
Aging Cell; 2011 Jun; 10(3):551-4. PubMed ID: 21388493
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production.
Ter Braak B; Siezen CL; Lee JS; Rao P; Voorhoeve C; Ruppin E; van der Laan JW; van de Water B
Breast Cancer Res; 2017 Feb; 19(1):14. PubMed ID: 28173837
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy.
Tian D; Kreeger PK
BMC Syst Biol; 2014 Aug; 8():98. PubMed ID: 25115504
[TBL] [Abstract][Full Text] [Related]
12. A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis.
Mori S; Tran V; Nishikawa K; Kaneda T; Hamada Y; Kawaguchi N; Fujita M; Saegusa J; Takada YK; Matsuura N; Zhao M; Takada Y
PLoS One; 2013; 8(2):e57927. PubMed ID: 23469107
[TBL] [Abstract][Full Text] [Related]
13. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation.
Tworkoski K; Raab-Traub N
J Virol; 2015 Mar; 89(5):2590-602. PubMed ID: 25520502
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
15. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors.
Evdokimova V; Tognon CE; Benatar T; Yang W; Krutikov K; Pollak M; Sorensen PH; Seth A
Sci Signal; 2012 Dec; 5(255):ra92. PubMed ID: 23250396
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1 increases apical fibronectin in blastocysts to increase blastocyst attachment to endometrial epithelial cells in vitro.
Green CJ; Fraser ST; Day ML
Hum Reprod; 2015 Feb; 30(2):284-98. PubMed ID: 25432925
[TBL] [Abstract][Full Text] [Related]
17. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
18. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix.
Hermanto U; Zong CS; Li W; Wang LH
Mol Cell Biol; 2002 Apr; 22(7):2345-65. PubMed ID: 11884618
[TBL] [Abstract][Full Text] [Related]
19. Peripheral pain is enhanced by insulin-like growth factor 1 and its receptors in a mouse model of type 2 diabetes mellitus.
Tang Z; Cao F; Zhang H; Tang J; Li H; Zhang Y; Feng B; Wang H
J Diabetes; 2019 Apr; 11(4):309-315. PubMed ID: 30105862
[TBL] [Abstract][Full Text] [Related]
20. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.
Rapraeger AC
FEBS J; 2013 May; 280(10):2207-15. PubMed ID: 23375101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
